Although AKT signaling has been thoroughly investigated as a promising target for cancer therapy, with several peptide AKT inhibitors documented in the literature and some of them approved by the FDA for cancer treatment [69,70,71,72], its exploration in PCa remains scarce. Here, AKT1 is linked to cancer.